The effects of patient out-of-pocket costs on insulin use among people with type 1 and type 2 diabetes with Medicare Advantage insurance-2014-2018.
Carrie McAdam-MarxNatalia Ruiz-NegronJane M SullivanJamie M TuckerPublished in: Health services research (2023)
Capping average insulin OOPC at $35 per 30-day supply may help avoid cost-related insulin non-adherence in MA patients; efforts to address non-cost barriers to medication adherence remain important.
Keyphrases
- type diabetes
- glycemic control
- end stage renal disease
- ejection fraction
- chronic kidney disease
- insulin resistance
- newly diagnosed
- cardiovascular disease
- case report
- affordable care act
- metabolic syndrome
- quality improvement
- peritoneal dialysis
- healthcare
- patient reported outcomes
- adipose tissue
- skeletal muscle
- long term care